WASHINGTON – Danaher Corporation, a global science and technology company, has entered into a definitive agreement to acquire Masimo Corporation, a specialty diagnostics provider of pulse oximetry and ...

Masimo Corporation (Nasdaq: MASI) (“Masimo”), a leading global innovator in patient monitoring, today announced that its stockholders voted in favor of the proposal to adopt the previously announced ...

Masimo (Nasdaq:MASI) announced today that its shareholders voted in favor of the proposed acquisition of the company by Danaher (NYSE:DHR). In February, Danaher and Masimo announced an agreement that ...

Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET ® pulse oximetry among critically ill neonates and demonstrating less than 1% overall statistical ...

These promising results—from an NIH-funded study that exclusively evaluated Masimo SET ® in a vulnerable, clinically fragile patient population—add to previously published evidence of its strong ...

NICU Study Adds to the Evidence Demonstrating SET®’s Accuracy in Challenging Real-World Settings, With No Clinically Significant Differences in Performance Across Skin Pigmentation Categories or Race ...

Masimo Corp. today reported study data showing that its pulse oximetry technology accurately monitored hospitalized newborns of all skin tones without dangerous drops in blood oxygen. The findings ...